Rib-X Pharmaceuticals, Inc.: Series E $20M

Posted in I - Series E, Q - 1Q11, R - NORTH EAST, X - Antiinfective, X - Bronchitis, X - MRSA, X - Pneumonia, XX - CT

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $20M Series E financing. Participants have included Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

Nov

2010

Dicerna Pharmaceuticals, Inc.: Series B $4M

Posted in I - Series B, Q - 4Q10, R - NORTH EAST, X - RNAi, XX - MA

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $4M Series B financing, bringing the total round to $29M. Participants include SR One, Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

Aug

2010

Dicerna Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - RNAi, XX - MA

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $25M Series B financing. Participants include Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

Apr

2010

Tragara Pharmaceuticals, Inc.: Series B $5M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Inflammation, X - Oncology, X - Pain, XX - CA

Tragara Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on selective biomarker for oncology, pain and inflammation therapeutics, closed a $5M Series B financing. Participants include Domain Associates, Mitsubishi Corp., Morgethaler Ventures, Oxford Bioscience Partners and ProQuest Investments.

Mar

2010

Seahorse Bioscience, Inc.: Series D $5M

Posted in I - Series D, Q - 1Q10, R - NORTH EAST, X - Device (Bioenergetics), XX - MA

Seahorse Bioscience (Billerica, MA) commercial-stage providers of instruments for cellular bioenergetic measurements for better understanding of the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity, closed a $5M Series D financing. Participants include Commonwealth Capital Ventures, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science [...]

Mar

2010

ImpactRx, Inc.: Series E $1.2M

Posted in I - Series E, Q - 1Q10, R - NORTH EAST, X - TeleMedicine, XX - NJ

ImpactRx (Mt. Laurel, NJ) a commercial-stage provider of online content measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation’s highest value physicians, closed a $1.2M Series E financing. Participants have included Mediphase Venture Partners, 3i Group, Oxford Bioscience Partners and Merck.

Feb

2010

CircuLite, Inc.: Series C $32.5M

Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Device (Cardiology), XX - NJ

CicuLite (Saddle Brook, NJ) a clinical-stage medical device company focused on minimally invasive implantable devices for chronic heart failure, closed a $32.5M Series C financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Foundation Medical Partners and Oxford Bioscience Partners.

to top of page...